随着AI深度融入设计全流程，如何运用系统思维搭建设计系统、掌握AI时代必备的prompt设计技能、挖掘AI在创作中的多元价值，同时明确设计师核心 价值转向与AI浏览器的未来形态，成为行业关注的重要课题。 IXDC有幸采访到微软产品设计师韩鹭，她就建立设计系统的核心系统思维经验、设计师掌握prompt设计的契机、高质量UI prompt的设计原则、AI在创作 中的多元作用、AI时代设计师的核心价值转向、未来AI浏览器的发展形态，进行了深入的探讨和分享。 IXDC：建立Edge设计系统时，您获得的最重要的系统思维经验是什么？ 韩鹭：建立设计系统的核心系统思维，并非单纯搭建控件库，而是"以产品全局视角思考设计"。做独立功能或页面改版时，需兼顾产品整体步调与未来发 展方向，让设计不仅满足当下需求，还具备充足的迭代空间与灵活性。这种全局化思维能让每一次设计输出都与产品长期发展适配，避免碎片化设计带来 的内耗。 IXDC：是什么契机让您意识到设计师必须开始掌握prompt设计这项新技能？ 韩鹭：核心契机是AI的快速发展与全流程赋能——AI已能融入设计从构思到产出的每一个阶段，成为强大的合作伙伴。若拒绝运用AI能力，本质上 ...

Core Viewpoint - Liu Ruopeng, Chairman of Guangqi Technology, disclosed the full-chain practice path of metamaterial technology from laboratory breakthroughs to industrialization at the "2025 Entrepreneur Boao Forum" [1] Group 1: Metamaterials - Metamaterials are referred to as the "gene editing technology" in the materials field, highlighting their importance in overcoming the limitations of natural material properties to achieve extraordinary performance through artificial customization [1] - The research has shifted from "material selection" to "functional customization," representing a successful practice of the "reverse design" paradigm [1] Group 2: Future Trends - Liu Ruopeng indicated that a large number of emerging technology companies driven by AI design will emerge, bringing not only disruptive technologies but also a complete restructuring of the existing industrial chain and division of labor [1]

Core Viewpoint - The in vivo CAR-T field has rapidly evolved over three years, marked by significant acquisitions and clinical advancements, culminating in major deals such as AbbVie’s $2.1 billion acquisition of Capstan Therapeutics and BMS’s $1.5 billion acquisition of Orbital Therapeutics [3][4]. Group 1: Acquisitions and Market Activity - AbbVie announced the acquisition of Capstan Therapeutics for $2.1 billion in cash, highlighting the growing interest in in vivo CAR-T therapies [3]. - BMS acquired Orbital Therapeutics for $1.5 billion, expanding its portfolio into the in vivo CAR-T cell therapy space [4]. - These acquisitions reflect a broader trend of increasing investment and collaboration in the CAR-T sector, indicating a robust market outlook [3][4]. Group 2: Technological Advancements - BMS's acquisition of Orbital enhances its cell therapy research platform, focusing on a potential best-in-class therapy aimed at autoimmune diseases [6]. - The therapy OTX-201, developed by Orbital, is in the pre-IND research stage and is expected to enter clinical trials in the first half of 2026 [6]. - OTX-201 utilizes optimized circular RNA (circRNA) to generate CAR-T cells in vivo, targeting CD19 to treat B-cell driven autoimmune diseases [7]. Group 3: Research and Development Focus - Orbital Therapeutics aims to develop next-generation RNA drugs that reprogram cells to treat diseases at their source, offering a simpler and safer alternative to current CAR-T therapies [10]. - The company’s platform integrates circRNA, linear RNA, targeted delivery systems, and AI-driven design to create durable and programmable therapies [10]. - In addition to autoimmune diseases, Orbital is also exploring in vivo CAR-T therapies for cancer and developing next-generation mRNA vaccines [12].